Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Patiromer Sorbitex Calcium
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : Vifor Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Veltassa® (patiromer) Approved in Japan For The Treatment of Adults with Hyperkalemia
Details : Veltassa (patiromer sorbitex calcium) is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older.
Product Name : Veltassa
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2024
Lead Product(s) : Patiromer Sorbitex Calcium
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : Vifor Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DIFICLIR (fidaxomicin) is a macrolide antibacterial medicine indicated as an initial treatment and first recurrence of Clostridioides difficile infection. Fidaxomicin treats CDI with minimal disruption to the microbiota, helping to preserve colonisation ...
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
July 12, 2021
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Astellas Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tillotts Pharma AG Continues Growth With Launch In Belgium, The Netherlands And Luxembourg
Details : Dificlir is an anti-toxin which contains the dynamic substance fidaxomicin used for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients.
Product Name : Dificlir
Product Type : Other Large Molecule
Upfront Cash : Inapplicable
May 20, 2021
Lead Product(s) : Fidaxomicin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Study Phase : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Agreement
Kyowa Kirin Terminates ASACOL® deal with Zeria Pharmaceutical
Details : Kyowa Kirin will finish its commercialization activity for ASACOL on March 31, 2020, and Zeria will obtain the full rights of the commercialization activities for ASACOL from April 1, 2020.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 02, 2020
Lead Product(s) : Mesalazine
Therapeutic Area : Immunology
Highest Development Status : Approved FDF
Sponsor : Kyowa Kirin
Deal Size : Undisclosed
Deal Type : Agreement